Public-domain · open source
OpenJurist
← 933 FSUPP2D 751 - In re Human Genome Sciences Inc. Securities Litigation

In re Human Genome Sciences Inc. Securities Litigation’s Empirical Analysis

2013

Citation profile

4
cited by 4 later decisions
October 2018
most recently cited

3 district ·

Relationships

Applies 15 U.S.C. § 78J (§ 10 of the Securities Exchange Act of 1934) · 15 U.S.C. § 78T (§ 20 of the Securities Exchange Act of 1934) · 15 U.S.C. § 78U (§ 21d of the Securities Exchange Act of 1934)

Relies on Bell Atlantic Corp. v. Twombly · Ernst & Ernst v. Hochfelder · Basic Inc. v. Levinson · Tellabs, Inc. v. Makor Issues & Rights, Ltd. · Superintendent of Insurance of State of New York v. Bankers Life and Casualty Company

Most-quoted passages

The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 4 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.

  1. “newspaper articles, analysts' reports, and press releases,”
    2 later decisions quote this exact passage · from the majority
  2. “In securities litigation cases premised upon a drug company's partial non-disclosure of drug trials to the investing public, the key inquiry is whether the non-disclosure at issue results in a suspiciously incomplete data set that yields a strong inference of scienter.”
    1 later decision quote this exact passage · from the majority
  3. “unless the controlling person acted in good faith and did not directly or indirectly induce the act or acts constituting the violation or cause of action.”
    1 later decision quote this exact passage · from the majority

How this case has been treated — in progress

Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.